Fibrobiologics, Inc. (FBLG) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Fibrobiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases, including wound healing, multiple sclerosis, and degenerative disc disease. The company operates as a single reporting segment and is classified as an emerging growth company and smaller reporting company. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5.78) million | $(15.40) million | $(8.06) million |
| Operating Expenses | $5.04 million | $14.06 million | $10.03 million |
| Cash and Equivalents (End of Period) | $4.87 million | $4.87 million | $7.83 million |
| Short-Term Convertible Debt | $4.57 million | $4.57 million | $9.17 million |
| Accumulated Deficit | $(50.92) million | $(50.92) million | $(32.42) million |
Note: The company has no revenue. Net loss includes significant non-cash charges related to the fair value of convertible debt and stock-based compensation.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended September 30, 2025, increased to $15.4 million from $8.1 million in the prior year period. This was driven by a $4.0 million increase in operating expenses.
- R&D Expense Growth: Research and development expenses rose to $6.6 million (YTD 2025) from $3.1 million (YTD 2024), primarily due to increased Contract Research Organization (CRO) costs ($2.1 million) to prepare for clinical trials and higher contract research costs for cell manufacturing.
- Debt Conversions: During the nine months ended September 30, 2025, the company converted approximately $9.7 million of short-term convertible debt into 13.1 million shares of common stock. This significantly reduced the principal balance of outstanding debt but resulted in a $0.9 million net loss on conversions.
- Cash Burn: Net cash used in operating activities increased to $13.2 million (YTD 2025) from $8.8 million (YTD 2024). Cash balances declined from $14.0 million at year-end 2024 to $4.9 million at September 30, 2025.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the issuance of the financial statements. The company relies on raising additional capital to fund operations.
- Capital Resources: The company entered into a Standby Equity Purchase Agreement (SEPA) in December 2024. As of September 30, 2025, $5.3 million of principal remains outstanding on the SEPA notes. The company has the right to require the investor to purchase up to an additional $10.0 million of shares.
- Clinical Trial Delays: The planned Phase 1/2 clinical trial for CYWC628 (diabetic foot ulcers) in Australia, originally expected to start in Q1 2026, has been delayed. The company is resolving manufacturing process issues and increasing aseptic process simulation runs to confirm sterility.
- Nasdaq Compliance Risks: The company received notifications from Nasdaq regarding non-compliance with the minimum bid price ($1.00) and minimum market value of listed securities ($35.0 million) requirements. Compliance periods extend to December 29, 2025, and February 2, 2026, respectively. Failure to comply could result in delisting.
- Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next capital raise given the $4.9 million cash balance and $13.2 million YTD operating cash burn.
- Manufacturing Status: Confirm the resolution of the aseptic process simulation issues delaying the CYWC628 clinical trial in Australia.
- Nasdaq Compliance: Monitor the stock price and market value to ensure compliance with Nasdaq Capital Market listing standards by the December 2025 and February 2026 deadlines.
- Dilution Impact: Assess the potential dilution from the remaining $5.3 million of convertible debt and the $10.0 million option under the SEPA, especially given the recent conversion prices dropping below $0.50 per share.
- Internal Controls: Review the remediation plan for the material weakness regarding segregation of duties in financial reporting.